Cardiology Research and Practice / 2019 / Article / Tab 2

Research Article

Predictors for New Native-Vessel Occlusion in Patients with Prior Coronary Bypass Surgery: A Single-Center Retrospective Research

Table 2

Procedural and angiographic characteristics of patients with or without a new CTO.

VariablesNo new CTO (n = 228)New CTO (n = 126) value

Preoperative angiogram
 Vessel stenosis at baseline0.001
  Moderate (40%–69%)
   LAD18 (7.89%)7 (5.56%)
   LCX18 (7.89%)6 (4.76%)
   RCA22 (9.65%)9 (7.14%)
  Severe (≥70%)
   LAD174 (76.32%)114 (90.48%)
   LCX123 (53.95%)89 (70.63%)
   RCA132 (57.89%)98 (77.78%)
  Coronary lesion category0.775
   Single-vessel disease18 (7.89%)8 (6.35%)
   Double-vessel disease62 (27.19%)31 (24.60%)
   Triple-vessel disease116 (64.47%)87 (69.05%)
  Left main involvement102 (44.74%)48 (38.10%)0.508
Total no. of patients with ≥1 CTO83 (36.40%)44 (34.92%)0.416
  Total of CTO vessel0.984
   LAD23 (10.09%)15 (11.91%)
   LCX15 (6.58%)7 (5.56%)
   RCA35 (15.35%)18 (14.29%)
   Multivessel8 (3.51%)3 (2.38%)
  Mean no. of bypass grafts3.0 ± 0.633.06 ± 0.750.599
  Types of graft0.460
   Internal mammary artery183 (80.26%)107 (84.92%)
   Saphenous vein2.22 ± 0.642.25 ± 0.73
  Graft patency0.522
   LIMA190 (83.33%)109 (86. 51%)
   SVG-D195 (85.53%)96 (76.19%)
   SVG-LCX/OM185 (81.14%)93 (73.81%)
   SVG-RCA/PDA163 (71.49%)84 (66.67%)
  Postoperative medication0.902
   Aspirin215 (94.30%)118 (93.65%)
   Statin185 (81.14%)98 (77.78%)
  Follow-up time (Mths)32.65 ± 15.8437.52 ± 17.390.175
  Free of symptom123 (53.94%)56 (44.44%)0.087
  Incomplete revascularization112 (49.12%)70 (55.56%)0.125

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.